Biological Products, (No Diagnostic Substances)
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Sector
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|
Net Margin | - | - | -28% | -740% | 21% | -600% | -300% | -44% | -46% |
ROA | - | -19% | -7% | -39% | 3.9% | -21% | -23% | -17% | -12% |
ROE | 92% | -19% | -6.6% | -50% | 6.2% | -30% | -31% | -14% | -9.4% |
The average Net Margin over the past 5 years is -281.54%.
The trend of Net Margin over the past 5 years is +17.79%.
The average ROA over the past 5 years is -17.18%.
The trend of ROA over the past 5 years is -0.85%.
The average ROE over the past 5 years is -21.01%.
The trend of ROE over the past 5 years is -0.5%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | - | - | - | - | - | - | - | - | - | |
Debt Equity | - | - | - | - | - | - | - | - | - | |
MIN | ||||||||||
Graham Stability | - | - | - | - | - | - | - | - | - |
The Debt/FCF trailing twelve month is -.
The trend of Debt/FCF over the past 5 years is -.
Graham’s Stability measure stands at -.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
---|---|---|---|---|---|
Revenue | - | 21% | -0.51% | 200% | -47% |
Net Income | - | - | - | - | - |
Stockholders Equity | - | 14% | -3.6% | -1.1% | -5.5% |
FCF | - | - | - | - | - |
The Revenue CAGR over the past 5 years is +20.67%.
The trend of Revenue growth rate over the past 5 years is -46.71%.
The Earnings CAGR over the past 5 years is +32%.
The trend of Earnings growth rate over the past 5 years is -.
The Equity CAGR over the past 5 years is +13.52%.
The trend of Equity growth rate over the past 5 years is -5.48%.
The FCF CAGR over the past 5 years is -.
The trend of FCF growth rate over the past 5 years is -.